Selecta Biosciences Stock News

NEW YORK , Dec. 14, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for GRTX, TMX, AGLE, ALZN, and SELB. … Full story available on Benzinga.com

Equities research analysts expect Selecta Biosciences, Inc. (NASDAQ:SELB) to post earnings of ($0.07) per share for the current quarter, Zacks Investment Research reports. Two analysts have provided estimates for Selecta Biosciences earnings, with the highest EPS estimate coming in at ($0.06) and the lowest estimate coming in at ($0.07). Selecta Biosciences reported earnings per share []

Selecta Biosciences Inc. (NASDAQ:SELB) price on Thursday, December 09, fall -4.72% below its previous days close as a downside momentum from buyers pushed the stocks value to $3.03. A look at the stocks price movement, the close in the last trading session was $3.18, moving within a range at $3.03 and $3.19. The beta value Selecta Biosciences Inc. (SELB) With A Potential Upside Of More Than -329.04% Read More »

Selecta Biosciences, Inc. (NASDAQ:SELB) has received an average recommendation of Buy from the eight research firms that are presently covering the company, Marketbeat reports. One research analyst has rated the stock with a sell rating and seven have assigned a buy rating to the company. The average 12 month target price among brokers that have []

Corporate insiders buy penny stocks & these 10 are getting purchased in December 2021. The post 10 Penny Stocks To Buy In December According To Insiders appeared first on Penny Stocks to Buy, Picks, N

Selecta Biosciences, Inc. (NASDAQ:SELB) Director Nishan M. Desilva purchased 7,000 shares of the businesss stock in a transaction on Thursday, December 2nd. The stock was purchased at an average cost of $2.96 per share, for a total transaction of $20,720.00. The transaction was disclosed in a document filed with the SEC, which is accessible through []

Selecta Biosciences, Inc. (NASDAQ:SELB) CEO Carsten Brunn sold 4,746 shares of Selecta Biosciences stock in a transaction on Thursday, December 2nd. The stock was sold at an average price of $2.96, for a total transaction of $14,048.16. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. []

STOCKHOLM, Dec. 1, 2021 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi) (STO: SOBI) and Selecta Biosciences, Inc. (NASDAQ: SELB), today announced the completion of enrolment for DISSOLVE

-DISSOLVE program on track with 12-month study fully enrolled- -DISSOLVE II on track for full enrollment in early 2022- -Top-line data from Phase 3 DISSOLVE program expected in H2 2022-

Medicure (OTCMKTS:MCUJF) and Selecta Biosciences (NASDAQ:SELB) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, valuation, dividends, analyst recommendations, earnings, profitability and institutional ownership. Profitability This table compares Medicure and Selecta Biosciences net margins, return on equity and return on [] The post Selecta Biosciences (NASDAQ:SELB) versus Medicure (OTCMKTS:MCUJF) Head-To-Head Comparison appeared first on ETF Daily News .

Black Friday Turns Red On "Terrible News" - Global Markets Crater On "Nu Variant" Panic The Friday after thanksgiving is called black Friday because that''s when retailers finally turn profitable for the year. Not so much for market, however, because this morning it''s red as far as the eye can see. The culprit: the same one we discussed late last night - the emergence of a new coronavirus strain detected in South Africa, known as B.1.1.529, which reportedly carries an "extremely high number" of mutations and is “clearly very different” from previous incarnations, which may drive further waves of disease by evading the body’s defenses according to South African scientists, and soon, Anthony Fauci. British authorities think it is the most significant variant to date and have hurried to impose travel restrictions on southern Africa, as did Japan, the Czech Republic and Italy on Friday. The European Union also said it aimed to halt air travel from the region. "Markets have been quite complacent about the pandemic for a while, partly because economies have been able to withstand the impact of selective lockdown measures.

The FDA has placed a clinical hold on Selecta Biosciences Inc''s (NASDAQ: SELB ) Phase 1/2 trial of SEL-302 (which consists of MMA-101 plus ImmTOR) for methylmalonic acidemia (MMA). MMA is a disorder in which the body cannot break down certain proteins and fats, resulting in a buildup of methylmalonic acid in the Full story available on Benzinga.com

The stock price of Selecta Biosciences Inc (NASDAQ: SELB) fell by over 12% pre-market today. This is why it happened.

The FDA issues a clinical hold on Selecta's (SELB) phase I/II study evaluating SEL-302 for the treatment of patients with methylmalonic acidemia. Shares down in after-hours trading.

Northern Trust Corp reduced its position in shares of Selecta Biosciences, Inc. (NASDAQ:SELB) by 17.1% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 607,927 shares of the companys stock after selling 125,556 shares during the quarter. Northern Trust Corp owned 0.54% []